Dov Elefant Buys 15,625 Shares of Femasys (NASDAQ:FEMY) Stock

Femasys Inc. (NASDAQ:FEMY) CFO Dov Elefant bought 15,625 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief financial officer directly owned 15,625 shares of the company’s stock, valued at $50,000. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Femasys Stock Performance

FEMY stock traded down $0.02 during midday trading on Tuesday, hitting $2.35. The stock had a trading volume of 228,436 shares, compared to its average volume of 120,035. Femasys Inc. has a 52 week low of $2.29 and a 52 week high of $22.20. The company has a current ratio of 3.91, a quick ratio of 1.98 and a debt-to-equity ratio of 0.53. The stock has a 50-day simple moving average of $3.87 and a 200 day simple moving average of $7.49. The firm has a market capitalization of $7.10 million, a price-to-earnings ratio of -0.44 and a beta of -2.08.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Friday, May 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $1.43. Femasys had a negative net margin of 521.97% and a negative return on equity of 258.08%. The firm had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.77 million.

Analysts Set New Price Targets

Several research analysts recently issued reports on FEMY shares. Wall Street Zen raised shares of Femasys to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings raised Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $80.00.

Hedge Funds Weigh In On Femasys

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kovack Advisors Inc. bought a new stake in shares of Femasys during the fourth quarter worth $27,000. HRT Financial LP acquired a new position in shares of Femasys during the fourth quarter valued at $30,000. Cetera Investment Advisers acquired a new position in shares of Femasys during the fourth quarter valued at $36,000. Osaic Holdings Inc. bought a new position in Femasys in the second quarter valued at about $45,000. Finally, State Street Corp increased its position in Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares during the period. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.